Zongertinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 60 mg, 90 mg, 120mg
Reference Brands: Hernexeos (USA)
Category: Oncology Cancer Care
Zongertinib is an oral, small-molecule, irreversible tyrosine-kinase inhibitor that selectively targets the human epidermal growth factor receptor 2 (HER2/ERBB2) including certain activating mutations in the tyrosine-kinase domain. It is indicated for adult patients with unresectable or metastatic non-squamous NSCLC whose tumors harbor HER2 (ERBB2) tyrosine kinase domain activating mutations and who have previously received systemic therapy. Zongertinib is available in Tablets and strengths such as 60 mg, 90 mg, 120mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Zongertinib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Zongertinib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Zongertinib is used to treat adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) that has HER2 (ERBB2) tyrosine kinase domain mutations and who have received prior systemic therapy.
Zongertinib is a synthetic small-molecule tyrosine kinase inhibitor that selectively targets HER2 mutations to block cancer cell growth and division.
The trade name of Zongertinib is Hernexeos.
It is developed and manufactured by Boehringer Ingelheim Pharmaceuticals.
The generic name is Zongertinib.
The brand name is Hernexeos.
Zongertinib is manufactured in the United States by Boehringer Ingelheim.
Related Products
Momelotinib
Strength:
100 mg, 150 mg, 200 mg
Form: Tablets
Reference Brands: Ojjaara (USA)
View Details
Nirogacestat
Strength:
50 mg
Form: Tablets
Reference Brands: Generic formulations marketed under different names
View Details
Nintedanib
Strength:
100 mg, 150 mg
Form: Capsules
Reference Brands: Ofev (USA, EU), Vargatef (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
